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Glioblastoma is the most devastating of brain cancers with a very high death rate 
and a low survival rate of less than 15 months after diagnosis. Glioblastoma is a cancer of 
astrocytes which are the majority of the brain glial cells that support neurons and help 
create the blood-brain barrier among other functions. The current approach to treating 
this disease is surgical removal of the main tumor, followed by radiotherapy and limited 
chemical intervention by the use of temozolomide (TMZ). This disease is characterized 
by high invasion and recurrence after surgical removal of the main tumor as a result of 
cancerous astrocytes migrating from the main tumor site to other parts of the brain. Novel 
dihydropyridines were synthesized and their effects tested on glioblastoma cell line U-
87MG to screen for their anti-cancer activities. Cell viability assays were performed to 
 
 
establish the (lethal concentration) LC50 of these compounds. The novel hybrid 
dihydropyridines reduced the cell viability of U-87MG cells, with the substituted 
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Cancer, a collection of diseases characterized by uncontrolled cell division results 
in the destruction of body tissues and patient death if untreated. The uncontrolled cell 
division is a result of genetic mutations that can be inherited or acquired during the 
person’s lifetime. Exposure to various carcinogens (cancer-causing agents) can lead to 
these mutational events.  Most cancer develops in stages characterized by cellular 
changes starting with hyperplasia (an increase in the cell division), followed by dysplasia, 
(a noticeable change in morphology of the cells), which then leads to the development of 
in-situ cancer (a stationary form of cancer), and finally malignant cancer (capable of 
invading and metastasizing).  
Cancer diseases have created a burden on the world’s population with an 
estimated 18.1 million new cases and 9.1 million deaths in 2018 (Bray et al., 2018). Of 
the 9.1 million cancer deaths, the leading causes include lung, breast, prostate, and 
colorectal cancer, making these four cancers the most commonly studied. However, less 
common cancers such as brain cancers deserve research attention.  
Brain cancers with an incident rate of 1.6 % of all cancers worldwide may be 
counted as one of the rarer cancers (Bray et al., 2018). One of the most lethal and fastest 




been of interest lately in the US as it has claimed the lives of two US Senate members 
within the span of 10 years. This cancer is Glioblastoma multiforme. 
 
Glioblastoma Multiforme 
Glioblastoma multiforme (GBM), with a survival rate of less than 5%, has the highest 
death rate in comparison to all the other brain cancers (Da Fonseca et al., 2011), and most 
patients die within two years of diagnosis (Gallego, 2015).  GBM mostly targets the 
elderly and is more common in males (Morgan et al., 2017). GBM can be divided into 
primary and secondary depending on the genetic pathways involved.  The primary GBM 
affects the elderly with a mean age of 64, while secondary GBM affects younger people 
with a mean age of 45 years old (Ohgaki et al., 2004). Genetically, primary and 
secondary GBM have characteristic mutations. Primary GBM (80%) is characterized by 
high expression of epidermal growth factor receptor, while secondary GBM (20%) is 
associated with overexpression of mutant TP53 gene (Kleihues and Ohgaki, 1999).  
GBM is a glioma which originates from astrocytes while other gliomas can arise 
from different glial cell types such as oligodendrocytes (Zong et al., 2012). Verkhratsky 
and Butt (2013) state that astrocytes constitute the largest proportion of the brain glial 
cells (20-50%). These star-shaped cells have multiple brain functions including secretion 
of the extracellular matrix, uptake, and regulation of neurotransmitters, and regulation of 
the blood-brain barrier. 
  The World Health Organization (WHO) has divided astrocytomas into four 
groups or grades (increasing in severity) based on morphological, cellular, genetic and 




benign cystic tumors in the cerebral hemispheres, affecting mostly young people (Huang 
et al., 2005). Grade II is low-grade astrocytoma, associated with infiltration and targets 
young to middle aged people, 20-50 years old. Grade III is anaplastic astrocytoma; it is a 
rare but malignant type of cancer. It is characterized by invasion but can be distinguished 
from glioblastoma by its inability to infiltrate the blood vessels. Grade IV or GBM is 
characterized by high proliferation and invasion. 
 
Invasion 
GBM cells aggressively invade the normal brain tissue and surrounding blood vessels 
which reduces the effectiveness of tumor resection. The micro-tumors (small tumors that 
form around the main tumor mass) also referred to as neurospheres are usually found 
about 3 cm away from the primary tumor area (Lara-Velazquez et al., 2017), where they 
are shielded from the radiation therapy by embedding into normal tissue. The invasive 
cells migrate through the space surrounding the blood vessels called the perivascular 
space. They can also travel through the brain parenchyma and white matter neuronal 
tract. 
  There are two ways in which the glioblastoma cells can invade the surrounding 
tissue: as a single cell or as a sheet of cells (collective migration) from the primary tumor 
(Gandalovičová et al., 2017). Glioblastoma cells can invade because they are transformed 
to be mobile, gain the ability to degrade extracellular matrix and increase the expression 
of necessary enzymes for these processes. The cells first develop membrane extensions 
(invadopodia) as a morphological change which allows them to attach to the extracellular 




extracellular matrix glycoprotein is highly expressed in glioma cells and promotes the 
formation of membrane extensions for migration. 
Invasive cells produce proteolytic degradation enzymes (matrix 
metalloproteinases) that allow them to degrade the extracellular matrix for invasion 
(Gandalovičová et al., 2017). These matrix metalloproteinases (MMPs) are produced in 
all cancers during progression and growth (Egeblad and Werb, 2002). High levels of two 
metalloproteases (MMP-2 and MMP-9) are expressed in glioblastoma cells and are 
believed to aid in extracellular matrix degradation during the invasion (Ramachandran et 
al., 2017). MMP-2 and MMP-9 are upregulated in the glioblastoma cells during the 
invasion phase through the Hedgehog pathway (Chang et al., 2015).  
Another protein family involved in migration and invasion is ADAM (a 
disintegrin and metalloprotease domain); these proteins cleave and therefore inactivate 
CD44 a cellular adhesion molecule, among other functions, which leads to cell migration 
(Takamune et al., 2008). Nakamura et al. (2004) discovered a high expression of ADAM-
12 and ADAM-17 enzymes in glioblastoma cells which presents as a potential target for 
anti-invasive drugs. These ADAM proteins are upregulated in glioblastoma and aid in the 
cell proliferation by increasing the amount of tumor necrosis factor through prodomain 
shedding (Kodama et al., 2004). 
 
Neurospheres 
Neurospheres are spherical structures that form in vitro from the cells or tissue of 
embryonic or adult central nervous system (Reynolds and Weiss, 1992). They are 
characterized by the ability to self-renew, proliferate and differentiate. Prior to the 




undergo neuronal genesis. Kaplan and Hinds (1977), however, managed to show that new 
neurons could be formed in an adult brain. The discovery of neuronal stem cells and the 
development of neurospheres were then successfully propagated from the hippocampus 
of the rat (Reynolds et al., 1992).  
Neurospheres are physically characterized by a few neuronal stem cells which 
rapidly divide and get embedded into already differentiating cells.  They are formed from 
the culturing of neuronal stem cells which originate from the sub ventricular zone or sub 
granular zone of the hippocampus (Pastrana et al., 2011). When the tissue from these two 
regions of the brain is cultured in media that promotes cell proliferation, then cells grow 
into small aggregations of de-differentiated cells. Neurospheres can also form from brain 
cancer stem cells (Kim et al., 2015).  
Neurospheres provide a good study model of tumor formation in brain cancer. 
Reynolds and Weiss (1992) showed that the study of neurospheres can improve the 
prognosis of gliomas as they can be used as biomarkers for tumor development. They are 
also used to study brain cell and tissue regeneration as well as neuronal stem-like 
characteristics. Studying neurospheres formed from tumors can lead to medicinal 
therapies that prevent cancer relapse by targeting cancer stem cells (Gilbert and Ross, 
2009). 
 
GBM Treatment Regimen 
GBM is generally treated by surgery, radiotherapy, and chemotherapy. Surgery is 
helpful in removing the primary tumor mass, but it does not remove all the cancer cells as 




reduces the number of remaining cancer cells around the primary tumor site; but this 
method is not effective as many of the invasive cells have migrated far from the initial 
tumor mass (Giese et al., 2003). In conjunction with surgery and radiation therapy, 
patients are also treated with chemotherapeutic agents, the most common one being 
temozolomide (TMZ). This drug targets the invasion process by altering DNA bases in 
GBM cells through methylation (Stupp et al., 2005). However, TMZ is highly susceptible 
to resistance as the cancer cells mutate (Gallego, 2015). Castro and Aghi (2014) tested 
another drug used to treat GBM called bevacizumab, which targets angiogenesis. This 
drug has helped increase the survival for some patients by a few years, however, because 
of the development of drug resistance and the high death rates for most patients, it is not 
optimal. There is a need to develop new additional drugs for the treatment of GMB. 
 
Hybrid Compounds 
For decades, scientists and medical personnel have focused on the single 
molecule-single target paradigm in drug discovery where a single very specific target of 
the disease is addressed (Kong et al., 2009). Diseases, however, are complex in nature, 
rarely resulting from a single abnormality but have complex networks and different 
factors contributing to their development (Scotti et al., 2017). Complex diseases such as 
malaria and cancer are also prone to drug resistance due to mutations in the target. One 
approach to overcome the issues of complexity and resistance is the use of combination 
drugs. This method involves a cocktail or mixture of single target drugs so that the drugs 




resistance, low margin of safety, and adverse side effects (Berube 2016), therefore new 
strategies for drug development were needed. 
  A new paradigm of drug discovery, the use of hybrid drugs, is now being 
investigated. This method of drug discovery has developed over the past two decades 
with studies of malaria (Cavalli and Bolognesi, 2009) and cancer. The advancement in 
cellular/molecular biological techniques in the areas of genomics, proteomics, and 
genetics has provided new targets for drugs and facilitated this approach. 
 For example, bleomycin; a three-component anti-cancer hybrid drug was among 
the first be studied in early 2000 (Meunier, 2008). The other drug on the pioneering 
forefront in hybrid drug studies is artemisinin which is an anti-malarial pharmacophore (a 
part of the molecule that has biological activity) which has been studied since the 1980s 
(Muregi and Ishih, 2010). The FDA has also noted an increase in multitarget drugs since 
the 2000s (Ramsay et al., 2018).   
Hybrid drugs are medications composed of two or more pharmacophores 
covalently bonded together into a single molecule (Micheal, 2017). These molecules can 
be formed through conjugation whereby a molecular linker is used to join the 
pharmacophores together. They can also be fused molecules which result from the direct 
linkage of pharmacophores via a functional group or merged molecules in which the 
pharmacophores are attached together without a linker, but instead, they are formed due 
to overlapping motifs (Gediya and Njar, 2009).  
Many hybrid drugs appear to improve the pharmacodynamics and 
pharmacokinetics of the drugs. They have also been found to reduce resistance to drugs 




developing hybrid drugs for cancer therapy. There is a potential increase in drug efficacy 
when using hybrids as they have more than one biological target. Some anti-cancer 
hybrid drugs are being developed to decrease drug turnover, increase efficacy, delivery, 
lower toxicity, and reduce resistance to chemotherapy drugs. The use of hybrid drugs 
instead of combination drugs lowers the dosage of drugs administered which is likely to 
increase the safety margin of the drug. 
 
Dihydropyridines 
Dihydropyridines are heterocyclic compounds. They are synthesized through a 
Hantzsch dihydropyridine synthesis process which is a condensation reaction of 
aldehydes (organic compounds with carbon double-bonded to oxygen) with two beta-
ketoesters (a ketone on the beta-carbon of an ester) and a nitrogen-donating group usually 
an ammonium salt (Velena et al., 2016).  
Most dihydropyridines are known for their role in reducing blood pressure with a 
number of derivatives that are FDA approved for treatment (Fig. 1). They are calcium 
channel blockers which block L-type calcium channels thereby relaxing the cardiac 
smooth muscles allowing for more blood flow. However, dihydropyridines have 
demonstrated anti-cancer activities in breast cancer (Naziroglu et al., 2017) and HeLa 
cancer cells (Firuzi et al., 2013). They also inhibit the influx of calcium and this 







Figure 1: The generic structure of commercially available dihydropyridines, with 
an electron withdrawing group at position R.  
 
 Dihydropyridines act on GBM cells by inhibiting the T-voltage gated calcium 
channels (prominent in invasive cells) and calcium activated potassium channels which 
contributes to cancer cell survival (Niklasson et al., 2017). Niklasson et al. (2017) 
demonstrated that the dihydropyridine nifedipine increased the median survival rate in a 
GBM mouse model. These compounds also reduce the rate of invasion and migration of 
tumor cells by inhibiting the activation of ADAM10 in pancreatic cancer (Woods et al., 
2015). ADAM 10 enhances cell proliferation and invasion by activating a cascade that 
requires calcium; therefore, blocking calcium influx inhibits this process (Woods et al., 
2015). 
In other cancer studies dihydropyridines showed major activity against the 
development of multidrug resistance. Dihydropyridines inhibit the P-glycoproteins which 
are involved in drug resistance (Zhou et al., 2005).  Studies have shown that 
dihydropyridines elevate the cellular concentration of mitoxantrone (a chemotherapy 
drug) four-fold in comparison to initial levels. Firuzi et al., (2013) demonstrated that 




A pharmacophore of interest is boronic acid. Boronic acids are Lewis acids 
belonging to the organoborane group and is characterized by the presence of a carbon-
boron bond. Boronic acid functional group is found in the anti-cancer drug bortezomib, 
used to treat prostate and bladder cancer (Lashinger et al., 2005). Scarano et al. (2013) 
used boronic acid as a means of drug delivery in an ovarian cancer cell line through its 
ability to bind cell surface carbohydrates. The boronic acid pharmacophore has also been 
shown to increase drug lipophilicity which promotes drug passage across cell membranes 
(Issa et al., 2011). 
 
Objectives and Hypothesis 
In this research, I will: (1) synthesize novel hybrid dihydropyridine compounds, 
(2) determine the effects of these compounds on cellular cytotoxicity and determine the 
lethal concentration (LC50) of these compounds in U-87MG cells, (3) document the 
effects of the hybrid compounds on cell morphology and neurosphere formation, (4) 
measure the effects of the compounds on cell migration, and (5) measure the effects of 
the hybrid compounds on cell invasion.  I hypothesize that novel dihydropyridine 
derivatives will reduce the growth and proliferation of U-87MG cancer cells as well as 














Seventeen novel hybrid dihydropyridine molecules were synthesized and tested 
for their anti-cancer and anti-invasion activities on the U-87MG glioblastoma cell line. 
They were synthesized using the classical Hantzsch dihydropyridine synthesis reaction. 
This involves the condensation of an aldehyde, two equivalents of a beta-keto ester and a 
nitrogen donating ammonium salt which gives 1,4-dihydropyridine carboxylates.   
The mechanism for dihydropyridine synthesis involves a few more classic 
mechanisms to make necessary intermediates. A Knoevenagel condensation product is 
formed as an intermediate through the condensation of an aldehyde and one of the beta-
keto esters. Another important intermediate that is formed is the ester enamine made from 
the condensation of the other beta-keto ester with the ammonium salt. The further 
condensation of these two intermediates through Michael addition created the final 
product of 1,4-dihydropyridines. 
 Novel hybrid dihydropyridines were synthesized using substituted aromatic, 
heteroaromatic aldehydes and substituted cinnamaldehydes. The experimental procedure 
to synthesize these dihydropyridines involved the reflux of all the reagents in water and 






Hantzsch Reaction Mechanism 
 










The substituted benzaldehydes, heteroaromatic aldehydes, and substituted 
cinnamaldehydes were purchased from Aldrich, Acros Organics and Frontier Science. 
The starting materials and products were analyzed and confirmed using 1H NMR 
spectroscopy performed on a 400 MHz JEOL JNM-ECP400 FT NMR instrument and 




Figure 3: General equation for formation of dihydropyridines.  
 
 
The solvents, 16.5 ml water and 3.5 ml ethanol, were added to a 50 ml round 
bottom flask containing a magnetic stir bar. The following materials were then added in 
order: 2.5 mmol aldehyde, 5.0 mmol ammonium carbonate, 2.5 mmol boric acid, and 5.0 
mmol ethyl acetoacetate. The water-cooled condenser was attached to the round bottom 
flask and the reaction mixture refluxed for 6 hours. The mixture was then poured into a 
beaker containing 25 ml of saturated NaCl in ice and stirred for 10 minutes to terminate 
and neutralize the reaction. The reaction mixture was vacuum filtered and air dried to 
collect the solid product. The product was collected and weighed to calculate the percent 




sulfoxide (DMSO) as the solvent to identify and confirm the desired products. Infrared 
spectroscopy (IR) was used to further elucidate the structures of the dihydropyridines 
made by analyzing the presence and/or absence of functional groups. 
 
Results 
Below is a list of novel hybrid compounds synthesized during this project. The list 
indicates the name of the compound, the acronyms that will be used from henceforth to 
refer to them and the NMR and IR results of the relevant peaks in identifying the 
dihydropyridine. Figures 4 and 5 show structures of synthesized compounds. 
The starting materials showed an NMR diagnostic peak of the aldehydes between 
9.7-10 ppm chemical shift representing the proton on the aldehyde and the IR diagnostic 
peak around the 1630-1820 region representing the carbon- oxygen double bond. These 
peaks, however, were not present in the products, showing that all the aldehydes had 
reacted forming dihydropyridines. The products had NMR diagnostic peak between 
position 4.5-5 ppm showing the proton at position 4 of the dihydropyridine ring. The IR 
spectroscopy of the products had strong peaks between region 3100-3550 for the N-H 
bond in the dihydropyridine ring. 
 
Dihydropyridine NMR & IR Data 
 
(Diethyl 2, 6-dimethyl-1, 4-dihydropyridine-3, 5-dicarboxylate-3-yl) boronic acid:(3-
FPB) IR (ATR cm):3336 (N-H Stretch), 2980 (C-H Stretch), 1673 (C=O), 1485 (C=C); 
H NMR (400 MHz, DMSO-d6) ẟ: 1.15-1.10(6H, q, CH), 2.50 (6H, s, CH), 4.00 (4H, 
q,CH), 4.83 (1H, S,CH), 7.89(3H,m, Ar-H), 8.84 (1H,s,NH)    
 
(Diethyl 2, 6-dimethyl-1, 4-dihydropyridine-3, 5-dicarboxylate-4-yl) boronic acid: (4-




DMSO-d6) ẟ: 1.09-1.13(6H, q, CH), 2.25 (6H, s, CH), 3.97 (4H, q,CH), 4.83 (1H, S,CH), 
7.01(3H,m, Ar-H), 8.9 (1H,s,NH)    
 
Diethyl 2, 6-dimethyl-4-(2-fluorophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylate: (2-F) 
IR (ATR cm):3330 (N-H Stretch), 2981 (C-H Stretch), 1691 (C=O), 1484 (C=C); H 
NMR (400 MHz, DMSO-d6) 
 
Diethyl 2, 6-dimethyl-4-(3-fluorophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylate: (3-F) 
IR (ATR cm):3340 (N-H Stretch), 2981 (C-H Stretch), 1647 (C=O), 1477 (C=C); H 
NMR (400 MHz, DMSO-d6) ẟ: 1.09-1.13(6H, q, CH), 2.26 (6H, s, CH), 7.01(3H,m, Ar-
H), 9.0 (1H,s,NH)      
 
Diethyl 2,6-dimethyl-4-(4-fluorophenyl)-1,4-dihydropyridine-3,5-dicarboxylate: (4-F) IR 
(ATR cm) :3340 (N-H Stretch), 2984 (C-H Stretch), 1651 (C=O), 1505 (C=C); H NMR 
(400 MHz, DMSO-d6) ẟ: 1.09-1.14(6H, q, CH), 2.25 (6H, s, CH), 3.97 (4H, q,CH), 4.83 
(1H, S,CH), 7.01(3H,m, Ar-H), 8.9 (1H,s,NH)    
 
Diethyl 2,6-dimethyl-4-(2,3-fluorophenyl)-1,4-dihydropyridine-3,5-dicarboxylate: (2,3-
DF) IR (ATR cm) :3342 (N-H Stretch), 2980 (C-H Stretch), 1648 (C=O), 1478 (C=C); H 
NMR (400 MHz, DMSO-d6) ẟ: 1.04-1.09 (6H, q, CH), 2.35(6H, s, CH), 3.93 (4H, 
q,CH), 5.14 (1H, S,CH), 7.04-1.0 (3H,m, Ar-H), 8.95 (1H,s,NH)    
 
Diethyl 2,6-dimethyl-4-(2,4-difluorophenyl)-1,4-dihydropyridine-3,5-dicarboxylate:  
(2,4-DF) IR (ATR cm) :3373 (N-H Stretch), 2979 (C-H Stretch), 1677 (C=O), 1495 
(C=C);H NMR (400 MHz, DMSO-d6) ẟ: 1.05-1.10 (6H, q, CH), 2.50 (6H, s, CH), 3.93 
(4H, q,CH), 5.07 (1H, S,CH), 6.92-7.23 (3H,m, Ar-H), 8.86 (1H,s,NH)    
 
Diethyl 2,6-dimethyl-4-(2,5-difluorophenyl)-1,4-dihydropyridine-3,5-dicarboxylate: (2,5-
DF) IR (ATR cm) :3334 (N-H Stretch), 2928 (C-H Stretch), 1650 (C=O), 1488 (C=C);H 
NMR (400 MHz, DMSO-d6) ẟ:1.05 (6H, q, CH), 2.5 (6H, s, CH), 3.97 (4H, q,CH), 5.07 
(1H, S,CH), 7.00 (3H,m, Ar-H), 8.97 (1H,s,NH)    
 
Diethyl 2,6-dimethyl-4-(2-trifluoromethyl-phenyl)-1,4-dihydropyridine-3,5-
dicarboxylate:  (2-TF) IR (ATR cm) :3325 (N-H Stretch), 2981 (C-H Stretch), 1696 
(C=O), 1488 (C=C);H NMR (400 MHz, DMSO-d6) ẟ: 1.03-1.07 (6H, q, CH), 2.43 (6H, 
s, CH), 3.90 (4H, q,CH), 5.40 (1H, S,CH), 7..46-7.82 (4H,m, Ar-H), 9.00 (1H,s,NH)    
 
Diethyl 2,6-dimethyl-4-(3-trifluoromethyl-phenyl)-1,4-dihydropyridine-3,5-




(C=O), 1487 (C=C); H NMR (400 MHz, DMSO-d6) ẟ: 1.06-1.11(6H, q, CH), 2.28 (6H, 
s, CH), 3.97 (4H, q,CH), 4.90 (1H, S,CH), 7.45 (3H,m, Ar-H), 9.10(1H,s,NH)    
 
Diethyl 2,6-dimethyl-4-(3-Chlorophenyl)-1,4-dihydropyridine-3,5-dicarboxylate:  (3-Cl) 
IR (ATR cm) :3319 (N-H Stretch), 2979 (C-H Stretch), 1647 (C=O), 1484 (C=C);H 
NMR (400 MHz, DMSO-d6) δ:1.1-1.14 (6H, t,CH), 2.49(6H,s,CH), 3.99 (4H, q, CH) 4.8 
(1H, s,CH), 7.1-7.2 ( 4H,m, Ar-H), 8.90 (1H, s, NH) 
 
Diethyl 2,6-dimethyl-4-(4-Chlorophenyl)-1,4-dihydropyridine-3,5-dicarboxylate: (4-Cl) 
IR (ATR cm) :3355 (N-H Stretch), 2983 (C-H Stretch), 1648 (C=O), 1485 (C=C); H 
NMR (400 MHz, DMSO-d6) ẟ: 1.1-1.14 (6H, t, CH), 2.51 (6H,s, CH), 3.99 (4H,q, CH), 
4.84 (1H,s,CH) 7.17-7.27 (4H, m, Ar-H), 8.89 (1H,s, NH)  
 
Diethyl 2, 6-dimethyl-4-(2-quinoline)-1, 4-dihydropyridine-3, 5-dicarboxylate: ( 2-Q) IR 
(ATR cm):3404 (N-H Stretch), 2977 (C-H Stretch), 1692 (C=O), 1591 (C=C); H NMR 
(400 MHz, DMSO-d6) ẟ: 
  
Diethyl 2,6-dimethyl-4-(4-quinoline)-1,4-dihydropyridine-3,5-dicarboxylate: (4-Q) IR 
(ATR cm) :3172(N-H Stretch), 2974 (C-H Stretch), 1643 (C=O), 1505 (C=C);  H NMR 
(400 MHz, DMSO-d6) ẟ: 0.82-0.87(6H, q, CH), 2.50 (6H, s, CH), 3.76 (4H, q,CH), 5.68 
(1H, S,CH), 7.60 (3H,m, Ar-H), 88.5 (1H,s,NH)    
 
Diethyl 2, 6-dimethyl-4-(5-methyl-2-furfural)-1, 4-dihydropyridine-3, 5-dicarboxylate: 
(5-M2-F) IR (ATR cm):3302 (N-H Stretch), 2987 (C-H Stretch), 1650 (C=O), 1492 
(C=C); H NMR (400 MHz, DMSO-d6) ẟ: 1.15-1.19 (6H, q, CH), 2.50 (6H, s, CH), 3.34 
(4H, q,CH), 4.59 (1H, S,CH), 6.47(3H,m, Ar-H), 8.89 (1H,s,NH)     
 
Diethyl 2, 6-dimethyl-4-(5-pyridine)-1, 4-dihydropyridine-3, 5-dicarboxylate: (5-P) IR 
(ATR cm):3340 (N-H Stretch), 2984 (C-H Stretch), 1651 (C=O), 1505 (C=C); H NMR 
(400 MHz, DMSO-d6) ẟ: 1.08-1.12 (6H, q, CH), 2.50 (6H, s, CH), 3.34 (4H, q,CH), 4.79 
(1H, S,CH), 6.47(3H,m, Ar-H), 9.05 (1H,s,NH)    
 
Diethyl 2, 6-dimethyl-4-(5-methyl-2-thiophene)-1, 4-dihydropyridine-3, 5-dicarboxylate: 
(5-M2-T) IR (ATR cm) :3342 (N-H Stretch), 2978 (C-H Stretch), 1689 (C=O), 1484 
(C=C);  H NMR (400 MHz, DMSO-d6) ẟ: 1.15-1.20 (6H, q, CH), 2.50 (6H, s, CH), 3.34 












Figure 4: The structures of the substituted aromatic novel hybrid dihydropyridines with 







Figure 5: The structures of substituted heteroaromatic novel dihydropyridine compounds 




The synthesis of dihydropyridines following Hantzsch reaction was successful 
after the optimization of the method. The method was optimized for solvent by using 
15% ethanol with 85% water. This eliminated the stickiness of the product and increased 
the yield. The method used was able to obtain yields similar to other methods such as the 
microwave closed system which has yields of around 50-70% (Demirayak et al. 2011). 
Optimization was also performed for reflux time that would give the most product, which 
was 6 hours. Ammonium carbonate was lost from the reaction via sublimation and 
deposition within the first few minutes of reflux, therefore, it was optimized by doubling 
the molarity of the salt in order to leave excess ammonium carbonate at the end of the 
reflux.   
The novelty of the dihydropyridines synthesized is reflected in the functional 




cinnamaldehydes. The compounds synthesized were substituted on their aromatic rings 
with boronic acid, fluorine or chlorine. The lack of commercial availability of 
cinnamaldehydes made the substituted styrl group of dihydropyridines hard to synthesize 
with only two products synthesized. These products, however, could not be extracted 
from the flask after vacuum filtration because they were sticking to the sides of the flask 
and to the filter paper. They were also heavily pigmented with deep red color which 
could result in assay interference during biological assays. 
Our novel hybrid dihydropyridines had boronic acids substituted at positions 3 
and 4 (3-FPB, 4FPB), fluorine, difluoro and trifluoromethyl substituted at positions 2, 3 
and 4 (2-F, 3-F, 4-F, 2, 3-DF, 2, 4-DF, 2, 5-DF, 2-TF, 3-TF) and chlorine substituted at 
positions 3 and 4 (3-Cl, 4-Cl). The heteroaromatic substituted dihydropyridine had 
substituted quinolones (2-Q, 4-Q), furfural (5-M2-F) and thiophenes (5-M2-T).  
These pharmacophores are known to have medicinal effects which include anti-
malarial and anti-cancer properties. The synthesized compounds were used for drug 
testing on U-87MG glioblastoma cells to measure their anti-invasion and anti-cancer 
properties. Some of our synthesized dihydropyridines have similar structures to 
commercially available dihydropyridines.  For example, amlodipine (anti-hypertensive 
drug) have highly electronegative group chlorine substituted in the ortho (2) position.  
This may infer that in addition to anti-cancer activities, our synthesized dihydropyridines 








Understanding the physical properties of these compounds help predict their 
biological interaction with the cells and their transportation to the target sites of the 
disease being treated. There is a need to predict whether the drugs being synthesized have 
the potential to reach their target. Since the synthesized drugs are for treating brain cancer 
it is reasonable to make predictions towards the bioavailability of these drugs. The main 
pharmacological effects of interest are lipophilicity, hydrophobicity and physical 
properties that would help predict the drugs oral bioavailability as well as the ability to 
cross the blood-brain barrier. 
Lipinski’s rules of drug oral bioavailability state a molecule is likely to have good 
absorption if it has the following: (i) Molecular weight (MW) is less than 500, (ii) 
Calculated octanol/water partition coefficient (logP) less than 5, (iii) Presence of less than 
5 hydrogen bond donors, and (iv) Presence of less than 10 hydrogen bond acceptors.  
This means that a small, highly lipophilic and hydrophobic molecule is likely to cross the 
intestinal lining and therefore have greater oral bioavailability.  Violation of one of 
Lipinski’s rules does not negate oral bioavailability, but it does reduce it. 
The blood-brain barrier (BBB) protects the central nervous system from external 
toxins and other chemicals entering the brain tissue. This barrier is made up of capillary 
endothelial tight junctions and glial cells which prevent chemicals from passing through. 
The brain interstitial fluid also has low plasma protein concentration which reduces the 
permeability of plasma protein-bound lipophilic proteins.  The chemicals that are able to 
pass through the blood-brain barrier should therefore be small, lipophilic and with low 




Drugs that have low molecular weight, are hydrophobic and lipophilic have a 
great chance of passing through the blood-brain barrier. Dihydropyridine calcium channel 
blockers have been used in the treatment of some brain diseases like Alzheimer’s disease 
(Paris et al., 2011) and prevention of Parkinson’s disease (Ritz et al., 2010).  
Using Lipinski's rules, a prediction can be made on whether the novel dihydropyridines 
can cross the blood-brain barrier. A cheminformatics web software Molinspiration 
(https://www.molinspiration.com/) was used to predict the pharmacological and physical 






















Table 1: Predicted values of biological activities of the synthesized compounds. 
 




3-FB 373.21 3.41 105.09 4 3 
4-FB 373.21 3.43 105.09 4 3 
2-F 347.39 4.03 64.64 5 1 
3-F 347.39 4.53 64.64 5 1 
4-F 347.39 4.55 64.64 5 1 
2,3-F 365.38 4.14 64.64 6 1 
2,4-F 365.38 4.17 64.64 6 1 
2,5-F 365.38 4.17 64.64 6 1 
2-TF 397.39 4.76 64.64 7 1 
3-TF 397.39 5.26 64.64 7 1 
3-Cl 363.84 5.04 64.64 5 1 
4-Cl 363.84 5.06 64.64 5 1 
 2-Q 380.44 3.99 77.53 5 1 
4-Q 380.44 4.15 77.53 5 1 
5-FT-2-T 379.24 2.98 105.09 5 3 
5-M-2-F 364.35 3.25 123.60 5 1 












  The use of software tools like molinspiration help predict the bioavailability of 
synthetic compounds. Although the results are just a prediction, they give information on 
synthesized compounds activity that helps predict the usefulness of the synthetic 
compound. The main elements predicted by this software were oral bioavailability, 
lipophilicity and the ability for the drug to pass through the blood-brain barrier. All but 3 
(3-TF, 3-Cl, and 4-Cl) of the novel hybrid dihydropyridines did not violate Lipinski’s 
rule of 5. A logP value greater than 5 was the violation for the 3 drugs. Violating only 
one of the rules, however, does not exclude the drug but does make it a less likely 
candidate.  
  An octanol/water partition coefficient (logP) is used to predict the lipophilicity of 
a compound by measuring the ability of a compound to interact with oil more than water. 
One of Lipinski’s rules on drug availability states that a viable drug should have a logP 
value less than 5; values between 0 and 5 show high lipophilicity and high 
hydrophobicity for negative values.  
The dihydropyridines synthesized are hydrophobic based on the general 
observation that the molecules do not dissolve in water. Hydrophobic molecules are 
nonpolar molecules that repel water and therefore do not dissolve in it. The 
dihydropyridine ring has a nitrogen that is a proton donor, two carboxylates at position 3 
and 5 that are hydrogen bond acceptors; these atoms and groups increase the 
hydrophilicity of the compound. The overall molecule, however, is hydrophobic because 





This observation was supported by the predicted total polar surface area (TPSA) 
of novel dihydropyridines as shown in Table 1. Polar surface area is the surface area of a 
molecule that arises from nitrogen or oxygen atoms plus hydrogen atoms attached to 
them in a molecule. The greater the TPSA the more likely the molecule is to form 
hydrogen bonds and therefore more hydrophobic. A TPSA of less than 140 indicates a 
more hydrophobic molecule and all the dihydropyridines have a low TPSA as indicated 
in the table. 
The results predicted by the molinspiration software suggest that the synthesized 
dihydropyridines have oral bioavailability, high lipophilicity and hydrophobicity, and 
they could pass through the blood-brain barrier. Commercially available dihydropyridines 
have been shown to pass through the blood-brain barrier in mice with Alzheimer’s (Paris 









In this project U-87MG glioblastoma cells were used to investigate the effects of 
novel hybrid dihydropyridines on this cancer. These cells were maintained in a 
humidified incubator at 5% carbon dioxide and 37 °C. The cells were cultured in 
minimum essential media (MEM) (Gibco) containing 10% fetal bovine serum (Gibco) 
and 100 U/ml penicillin/streptomycin antibiotics (Gibco). The cells were treated with 
trypsin/EDTA (Gibco) and routinely split with media change on a Monday, Wednesday, 
Friday schedule to maintain cell numbers at less than 80% confluency. 
 
Cell Count 
U-87MG cells were used to perform all the experimental screenings for the effects 
of novel dihydropyridines in glioblastoma cells.  A cell count was obtained by detaching 
the cells from the dish with 2 ml of trypsin/EDTA. Using the trypan blue cell exclusion 
method, the total number of cells were determined using a hemocytometer and 
calculations for the cells needed for experimentation as follows: 12-well plate 10 000 








Cell Viability Experimental Procedure 
Cell viability experiments were set up to calculate the lethal concentration (LC50), 
as well as the lowest effective concentration (LEC) for novel hybrid dihydropyridines in 
glioblastoma cells. A colorimetric MTT assay was first tried without success because of 
compound color interference. To eliminate this problem, a modified National Cancer 
Institute (NCI) assay was utilized (https://dtp.cancer.gov/discovery_development/nci-
60/methodology.htm).  Cells were released from the dish and counted using a 
hemocytometer to determine the total number of cells needed for the experiment. In a 12-
well plate (Falcon), 10 000 cells per well were introduced in 1 ml of MEM media and 
incubated for 24 hours. The compound to be tested was diluted in DMSO at 20 mg/ml to 
make stock solutions. After 24 hours, the compound was diluted into 11 concentrations 
ranging from 0.00195mg/ml to 2mg/ml in MEM media to a final volume of 1 ml. Old 
media was removed from the 12-well plate and the drug introduced to the plate by putting 
the 11 different concentrations plus a control well with new media (Fig 6). Previous 
experiments in the lab showed no impact on cell viability from DMSO at concentrations 
used in this experiment.  After 24 hours media was removed and cells were fixed using 
methanol for 5 minutes followed by staining with crystal violet for 5 minutes. Excess 
stain was removed by washing with water.  Cells were then counted and quantified by 
picking 3 consistent spots in the wells and counting the field of view.  The three field of 





Figure 6: The representation of a 12-well plate with the 11 different concentrations in the 




Three trials of the cell viability assay were run, and data were averaged. Standard 
deviation was calculated, and standard error bars established. Using linear regression, 
LC50 concentrations were calculated and established. To verify the calculated LC50, 9 
additional trial cell viability assays were performed at the linear regression-determined 
LC50 concentration. Cells were fixed and stained with crystal violet as above and 3 fields 









The cytotoxicity and the LC50 of 14 compounds as well as the starting material 
ethyl acetoacetate (EAA) were measured and calculated through the cell viability assay. 
Figures 7-21 showing the cell viability for the 11 concentrations of the drug treated cells 
and untreated cells. The experiments were carried out through 3 independent trials and 
the results were recorded. Statistical analysis was performed using Dunnett test, to find 
the difference between the drug concentrations and the control. The asterisks on the 
graphs show the lowest concentration that was significantly different from the control, 
with all higher concentrations also significantly different from the control.  
The dihydropyridines were cytotoxic with aromatic compounds more potent than 
the heteroaromatic compounds. Compounds with the same substituent on the aromatic 
ring but different position for example 3-FPB and 4-FPB had similar potency with the 














Figure 7: Cell viability assay of 3-FPB on U-87MG glioblastoma cells. Cytotoxicity of 
the drug was measured by counting the number of cells per well for the 11 different 
concentrations and control. The error bars show the standard error, n =3 independent 
experiments. The lowest concentration significantly different from control is 0.125mg/ml, 
p≤ 0.05 shown by *.  
 
 
Figure 8:  Cell viability assay of 4-FPB on U-87MG glioblastoma cells. Cytotoxicity of 
the drug was measured by counting the number of cells per well for the 11 different 
concentrations and control. The error bars show the standard error, n =3 independent 
experiments. The lowest concentration significantly different from control is 0.125mg/ml, 



























































Figure 9:  Cell viability assay of 2-Q on U-87MG glioblastoma cells. Cytotoxicity of the 
drug was measured by counting the number of cells per well for the 11 different 
concentrations and control. The error bars show the standard error, n =3 independent 
experiments. The lowest concentration significantly different from control is 0.125mg/ml, 
p≤ 0.05 shown by *.  
 
 
Figure 10:  Cell viability assay of 5-P on U-87MG glioblastoma cells. Cytotoxicity of the 
drug was measured by counting the number of cells per well for the 11 different 
concentrations and control. The error bars show the standard error, n =3 independent 
experiments. The lowest concentration significantly different from control is 0.125mg/ml, 




























































Figure 11: Cell viability assay of 3-Cl on U-87MG glioblastoma cells. Cytotoxicity of the 
drug was measured by counting the number of cells per well for the 11 different 
concentrations and control. The error bars show the standard error, n =3 independent 
experiments. The lowest concentration significantly different from control is 
0.03125mg/ml, p≤ 0.05 shown by *.  
 
Figure 12: Cell viability assay of 4-Cl on U-87MG glioblastoma cells. Cytotoxicity of the 
drug was measured by counting the number of cells per well for the 11 different 
concentrations and control. The error bars show the standard error, n =3 independent 
experiments. The lowest concentration significantly different from control is 




























































Figure 13: Cell viability assay of 2-F on U-87MG glioblastoma cells. Cytotoxicity of the 
drug was measured by counting the number of cells per well for the 11 different 
concentrations and control. The error bars show the standard error, n =3 independent 
experiments. The lowest concentration significantly different from control is 
0.03125mg/ml, p≤ 0.05 shown by *.  
 
Figure 14: Cell viability assay of 3-F on U-87MG glioblastoma cells. Cytotoxicity of the 
drug was measured by counting the number of cells per well for the 11 different 
concentrations and control. The error bars show the standard error, n =3 independent 
experiments. The lowest concentration significantly different from control is 



























































Figure 15: Cell viability assay of 4-F on U-87MG glioblastoma cells. Cytotoxicity of the 
drug was measured by counting the number of cells per well for the 11 different 
concentrations and control. The error bars show the standard error, n =3 independent 
experiments. The lowest concentration significantly different from control is 
0.0625mg/ml, p≤ 0.05 shown by *. 
 
 
Figure 16: Cell viability assay of 2,3-DF on U-87MG glioblastoma cells. Cytotoxicity of 
the drug was measured by counting the number of cells per well for the 11 different 
concentrations and control. The error bars show the standard error, n =3 independent 
experiments.  The lowest concentration significantly different from control is 



























































Figure 17: Cell viability assay of 2,4-DF on U-87MG glioblastoma cells. Cytotoxicity of 
the drug was measured by counting the number of cells per well for the 11 different 
concentrations and control. The error bars show the standard error, n =3 independent 
experiments. The lowest concentration significantly different from control is 
0.03125mg/ml, p≤ 0.05 shown by *. 
 
Figure 18: Cell viability assay of 2,5-DF on U-87MG glioblastoma cells. Cytotoxicity of 
the drug was measured by counting the number of cells per well for the 11 different 
concentrations and control. The error bars show the standard error, n =3 independent 
experiments. The lowest concentration significantly different from control is 



























































Figure 19: Cell viability assay of 2-TF on U-87MG glioblastoma cells. Cytotoxicity of the 
drug was measured by counting the number of cells per well for the 11 different 
concentrations and control. The error bars show the standard error, n =3 independent 
experiments. The lowest concentration significantly different from control is 
0.00781mg/ml, p≤ 0.05 shown by *.  
 
Figure 20: Cell viability assay of 3-TF on U-87MG glioblastoma cells. Cytotoxicity of the 
drug was measured by counting the number of cells per well for the 11 different 
concentrations and control. The error bars show the standard error, n =3 independent 
experiments. The lowest concentration significantly different from control is 





























































Figure 21: Cell viability assay of EAA on U-87MG glioblastoma cells. Cytotoxicity of 
this starting material was measured by counting the number of cells per well for the 11 
sdifferent concentrations and control. The error bars show the standard error, n =3 
independent experiments.  The lowest concentration significantly different from control is 
1 mg/ml, p≤ 0.05 shown by *.  
 
Linear regression was used to calculate the LC50 of the novel dihydropyridines 




































Table 2: LC50 values (M) for the 14 compounds and EAA calculated through linear 
regression.  
Compound LC50 mg/ml LC50 µM 
2-TF 0.00550 13.84  
3-TF 0.00757 19.04 
4-F 0.00987 28 
2-F 0.01253 50.89 
3-F 0.01768 50.89 
2,3-DF 0.01438 39.35 
4-Cl 0.01954 42.32 
3-Cl 0.02155 42.32 
2,4-DF 0.02450 67.05 
2,5-DF 0.02252 61.63 
3-FPB 0.05625 150.71 
4-FPB 0.05781 154.80 
2-Q 0.05781 151.95 
5-P 0.08875 267.82 
EAA 0.2107 208.54 
 





Figure 22: LC50 value confirmation through testing the cells with the LC50 concentration, 
n = 9. Error bars indicate standard error. 4-Cl has the average survival of 24% which is 
below 50 %. 
 
 
Figure 23: LC50 value confirmation through testing the cells with the LC50 concentration, 






































































Figure 24: LC50 value confirmation through testing the cells with the LC50 concentration, 
n = 9. Error bars indicate standard error. 
 
Discussion 
The heteroaromatic dihydropyridines (2-Q and 5-P; figure 9 and 10) had the least 
potency compared to the rest of the compounds which had aromatic groups. Variability 
was also noticed within the substituted aromatic dihydropyridine group’s activities. 
Contrary to speculation boronic acid pharmacophores were not as potent which leads to a 
conclusion that at least they are not compatible with dihydropyridines as hybrid 
compounds to treat glioblastoma cancer. Although the synthesis of dihydropyridines with 
boronic acids have been found in the literature, there is no information on these 
compound’s biological activities making this research important for understanding the 





































The hybrid dihydropyridines showed varied cytotoxicity effects on the 
glioblastoma cells which resulted in reduced numbers of viable cells after the drug was 
introduced. Eleven concentrations were used to establish the LC50 concentration which 
was used to identify compounds that had greater potency (lower concentration of LC50) 
as well as provide the lowest tested concentration for each compound which would 
provide working concentrations to test other parameters such as phenotypic changes, 
neurosphere changes, cell mobility, and invasive potential. 
The compounds that were tested had LC50 concentrations verified that ranged 
from 0.00550mg/ml-0.08875mg/ml.  Further refinement of the LC50 concentration was 
needed for compound 4-Cl.  The 11-concentration assay was modified by reducing the 
highest concentration to 0.5mg/ml from 2mg/ml.  This changed the LC50 from 
0.01945mg/ml to 0.0127mg/ml, which is a much lower and therefore a more promising 
LC50 for this compound. These LC50 values were comparable to those of cancer drugs 
that are FDA approved, especially temozolomide which had the LC50 more than 100µM 
(Holbeck et al., 2010).  The published LC50 of cancer drugs showed that drugs containing 
boronic acid for example bortezomib had lower LC50 3.6µM (Holbeck et al., 2010), 
which could be caused by the synergistic effects of the hybrid pharmacophores. 
The starting material EAA was tested for its effect on cell viability resulting in a 
LC50 value of 208.54µM. This value was higher than the novel dihydropyridines except 
for compound 5-P indicating that this starting material is less inhibitory as compared to 
the synthesized drugs. The LC50 values showed that heteroaromatic substituted 




concentration needed to kill 50% of the cells compared to the aromatic substituted 
dihydropyridines making these compounds less potent compared to the rest of the group.  
The aromatic substituted dihydropyridines were more potent but within this group 
some variability was observed. The boronic acid substituted dihydropyridines 3-FPB and 
4-FBP 0.05625mg/ml and 0.05781mg/ml (150.71µM and 154.80µM) were the least 
potent in this group. The published LC50 value of cancer drug bortezomib which has a 
boronic acid pharmacophore was 3.6µM which is very low compared to boronic acid 
containing hybrid dihydropyridines. It is possible that the addition of fluorine 
(bortezomib does not have fluorine) on the compound is causing a higher LC50 
concentration is possible and needs exploration, but this seems unlikely as fluorine has 
been shown to enhance cytotoxicity.  Boronic acid pharmacophores are known for drug 
delivery (Zhang et al., 2018) and have been shown to induce apoptosis and reduce 
autophagy. For example, bortezomib is one of the few glioblastoma drugs on the market 
(Zhang et al., 2014).    
The electron withdrawing group substituted dihydropyridines were more potent 
with the trifluomethyl 2-TF and 3-TF having the lowest LC50 of 0.00550mg/ml and 
0.00757mg.ml (13.84µM and 19.04µM) values followed by di-fluorides with LC50 values 
ranging from 0.00987mg/ml-0.01768mg/ml (28µM -50.89µM). The singly substituted 
fluoro- and chloro- compounds were within the same range.  Incorporation of fluorine 
and chlorine in drugs has been shown to increase the potency of the compounds by 
increasing cytotoxicity through DNA fragmentation (Ren et al., 1998) and inducing 
apoptosis (Cattaneo-Pangrazzi et al., 2000).  The data shows that the compounds reduced 




however does not indicate the mode of action for these drugs.  Further investigations 
need to be performed to establish the mode of action such as an activated caspase ELISA 
which would indicate if the drugs are activating apoptosis which is one of the main 
hallmarks of cancer. More experiments were carried out to investigate the effects of the 
compounds on glioblastoma by utilizing the concentration that resembled control to test 
whether the compounds affected cell mobility as well as their ability to invade. 
 
Scratch Assay 
This assay was performed to test the effects of novel dihydropyridines on the 
motility of U-87MG glioblastoma cancer cells. This characteristic could impact the 
ability of these cells to invade as migration is part of the process involved in cancer cell 
invasion. The lowest drug concentration used in the cell viability assay (0.00195mg/ml) 
was used to test for this variable. The following compounds were tested: 2-TF; 3-TF; 3-
Cl; 4-Cl; 2-F; 3-F; 4-F; 2,3-DF; 2,4-DF; 2,5-DF. These compounds were selected for 
their lower LC50 concentrations. 
 
Experimental Procedure 
U-87MG glioblastoma cells were used to perform this experiment. 100,000 cells 
were introduced into 60 mm cell culture dishes (Falcon) and allowed to grow to full 
confluency. These cells were maintained with 3 ml of minimum essential media in a 
humidified 37 °C and 5% carbon dioxide incubator until they reached full confluency. 
Media was removed and 3 ml novel dihydropyridines at 0.00195mg/ml 




scratch was made at the bottom of the well and pictures taken under the microscope to 
note the cell filling of the scratch. Pictures were taken on three consecutive days to 
compare cell filling of the scratch in compound treated dishes compared to control dishes. 
 
Results 
The scratch assay helped establish the effects of the drugs on cell filling of the 
scratch.  No difference was noted in cell filling between all compound tested cells and 




Figure 25: Scratch assay photos taken on consecutive days after introduction of 
compounds to cells, magnification 100X. The marked places show the area of the scratch. 




The results for the scratch assay showed no differences in cell filling of the 
scratch between the untreated cells (control) and the hybrid dihydropyridine treated cells 
for all the tested compounds. These results suggest that the novel hybrid compounds have 





dihydropyridines would reduce the motility of the glioblastoma cells therefore reducing 
their ability to invade new tissue. The compounds may have no effect on ADAM proteins 
which are involved in motility (Nakamura et al. 2004), which could be determined by 
further experiments such as ELISA and/or western blots. 
The lack of noticeable differences may have been caused by the low concentration 
of the drugs used. An increased concentration of the compounds could have an effect on 
the migration and should be examined. Another possible reason for the lack of 
differences between the treatment and control could be the time intervals. The cells were 
photographed every 24 hours which could have been too long to notice any difference.  
Reducing this interval may show differences. 
 
Invasion Assay 
The novel dihydropyridines were screened for their effects on the invasiveness of 
U-87MG glioblastoma cells. One of the main steps towards invasion is the ability for 
cells to cross the basement membrane as they migrate away from the primary tumor. A 
drug that reduces this ability has great potential for reducing invasion in glioblastoma 
cancer after surgical removal of the cancer. The specific compounds used for this 




The experiment was performed using the Cell Invasion Assay Kit and protocol 




with the basement membrane bases. The invasion chamber with the basement membrane 
inserts was warmed up to room temperature and rehydrated using serum free MEM 
media. 50,000 cells were added in serum free MEM media containing novel 
dihydropyridines at the concentration of 0.00195mg/ml. In the outer chamber MEM 
media containing fetal bovine serum (10%) was added to encourage cells to migrate. The 
plates were incubated for 24 hours in a humidified, 37 °C, 5% carbon dioxide incubator. 
After incubation, the media was removed from the Boyden chamber and using cotton-
tipped swabs the noninvasive cells were removed from the inside of the Boyden chamber. 
The basement membrane of the Boyden chamber was stained. Cells that passed through 
the membrane were stained dark purple and were counted under the microscope (Cell 
Biolabs CytoSelect).  
 
Results 
Figure 26 shows the average number of cells that passed through the basement 
membrane of the invasion chamber.  These results were obtained from an average of two 







Figure 26: The effects of substituted aromatic novel dihydropyridines on cell invasion in 
U-87MG glioblastoma cells. 2-TF is the only one statistically significant from the control 
p ≤ 0.05 (ANOVA and Post hoc). The error bars indicate standard error, n = 3 
independent experiments using an average of two wells in each experiment. 
 
Cell treated by 2-TF compound had a statistically significant reduction in number 
of invasive cells when compared to the control.  The remaining compounds had no 
statistical difference when compared to control. 
 
Discussion 
The treated cells were able to invade the basement membrane with only the 2-TF 
treated cells showing significant reduction in invasiveness. I therefore reject the 
hypothesis that the novel dihydropyridines would reduce the rate of invasion on 
glioblastoma cells except for 2-TF. The drug lercanidipine, a dihydropyridine has also 
been shown to reduce MMP-2 activity which is one of the proteins involved in invasion 
































These results, however, support the scratch test results in which the compound-
treated cells were mobile and able to fill the scratch the same as the control. More 
verification assays may be performed in the future, for example, the use of the modified 
U-87MG cells that are selective for invasion (Lu et al., 2004) will be necessary to 
perform these experiments.  The results showed only 2-TF having anti-invasive 
properties, which will be necessary to investigate its effects on invasion proteins such as 
MMP-2 and MMP-9 to give more insight on its targets. 
 
Neurosphere Assay 
Neurospheres are noticeable in vitro and they may have an effect in the formation 
of new tumors. The dihydropyridines synthesized may have effects on neurosphere 
development, size and number which could be a therapeutic target to reduce the risk of 
recurrence in glioblastoma. 
 
Experimental Procedure 
The experiment was performed following an assay developed by Dr. D. Smith. 
5000 cells per well were introduced into a 24-well plate and incubated in a humidified 37 
°C, 5% carbon dioxide incubator for 24 hours. Compounds were used at the LC50 
concentration and at 0.00195mg/ml which is the lowest hybrid drug concentration used in 
the viability assay (3 drugs per plate plus a control). The cells were incubated for 24 
hours and the wells for day 1 (2 wells per compound LC50 concentration and 
0.00195mg/ml concentration as well as 1 well for control) were fixed using methanol for 




by washing with water.  The plates were incubated for additional 48 hours and the wells 
for day 3 were fixed, stained and washed as above, then an additional 48-hour incubation 
for day 6 followed by fixing, staining and washing as above.  The number of 
neurospheres formed was counted, and the sizes estimated. Morphological features in 
terms of neurosphere size and number were observed. 
 
Results 
The neurospheres were observed for size and presence in a qualitative data 
collection. Table 3 shows the total number of neurospheres for 3 independent 
experimental set ups was recorded. The neurospheres were described as small (S), for 
starting to develop with a lot of U-87MG cells gathering around and large (L) for already 
developed with a solid material at the center and U-87MG cells protruding from the 
neurosphere or a lot of circular cells grouped together (Fig. 27). 
Figure 27: Images of neurospheres with the small starting (S) on the left and a 










Table 3: Total number of neurosphere counted and their sizes, n = 3. 
Compound Day 1 Day 3 Day 6 
3-FPB            0.00195 
 
                         LC50 
3S                5S 3 L 
0 1S 2 S 
4-FPB             0.00195 
 
                        LC50 
1L, 1 S 2 S, 1 L 2 L, 4 S 
1 S 0 1 S 
 2-Q                 0.00195 
 
                        LC50 
1 S 2 S, 1 L 2 L, 2 S 
1 S 1 S 1 S, 1 L 
Control 2 S 2 S, 1L 3 S, 4 L 
    
 
Compound Day 1 Day 3 Day 6 
5-P                 0.00195 
 
                         LC50 
2 S 3 S, 1 L 5 S, 3 L 
3S 3 S 1 S, 4 L 
2-F                  0.00195 
 
                        LC50 
2 S 2 S, 2 L 3 L 
1 S 2 S 1 S, 2 L 
3-F                    0.00195 
 
                         LC50 
2 S 3 S 6 S 
1 S 3 S 3 S, 3 L 
Control 3 S 2 S, 3 L 4 S, 2 L 
    
 
Compound Day 1 Day 3 Day 6 
4-F                   0.00195 
 
                           LC50 
2 S 3 S 3 L 
2 S 3 S 2 S, 2 L 





                        LC50 
1 S 2 S 2 S, 3 L 
2,4-DF              0.00195 
 
                        LC50 
2 S 2 S, 2 L 2 S,2 L 
0 0 2 S 
Control 6 S 3 S, 2 L 3 S, 3 L 
    
 
Compound Day 1 Day 3 Day 6 
 
  2,5-DF             0.00195 
 
 
                           LC50        
2 S 3 S 3 L 
0 2 S 2 S, 1 L 
2-TF              0.00195 
 
 
                            LC50 
2 S 3 L, 1 S 1 S, 3 L 
2 S 3 S 1 S, 3 L 
3-TF                 0.00195 
 
 
                              LC50 
2 S 3 S 2 S, 2 L 
1 S 2 S 2 L 
Control 3 S 3 S, 2 L 1 S, 3 L 
    
 
3-Cl                   0.00195 
 
                         LC50 
3 S 2 S, 1 L 3 L 
0  1 S 2 S 
4-Cl                  0.00195 
 
                        LC50 
3 S 3 S, 1 L 3 L 
0 0 0 





Substituted boronic acid compounds 3-FPB and 4-FPB gave a large number of 
neurospheres higher than control at concentration 0.00195 mg/ml for days 1 and 3 and 
had lower neurospheres at LC50 concentration. The substituted heteroaromatics (2-Q and 
5-P) developed neurospheres at both concentrations. The substituents fluorine and 
chlorines also developed neurospheres at concentration 0.00195 mg/ml and did not have 
many neurospheres at the LC50 concentration and in most cases the LC50 concentration 
resulted in delayed onset of neurospheres. 
 
Discussion 
 The introduction of drugs did not terminate the development of neurospheres, 
even at the LC50 concentration.  However, neurospheres from day one and day three were 
small and still developing with normal U-87MG cell morphology which seemed to 
indicate the compounds did slow development down. Day six neurospheres, however, 
presented as a large circle in the middle with cells protruding from them.  The 
compounds at LC50 concentration reduced the number, the size or the onset of 
neurospheres depending on the drug used. Temozolomide and carmustine cancer drugs 
have been shown to block neurosphere formation (Mihaliak et al. 2010). 
Substituted boronic acid compounds 3-FPB and 4-FPB presented a large number 
of neurospheres at the 0.00195 mg/ml concentration and appeared much like control 
while the LC50 concentration did seem to delay formation which suggest an inhibitory 
role in neurosphere formation. 
  Compounds 3-Cl, 4-Cl, 2,4-DF and 2,5-DF showed low numbers in neurosphere 




These compounds may have an effect on reducing neurosphere formation which could 
have a positive effect towards treating glioblastoma. Further investigations may need to 
be performed using selective neurosphere models to see the mode of action and results.  
Of all compounds tested, 4-Cl was the most promising for impacting development of 
neurospheres. 
The substituted heterocyclic dihydropyridines 2-Q and 5-P had neurospheres 
developing from day one in both the concentrations, although small. Quinolone 
derivatives have been shown to reduce the formation of neurospheres in glioblastoma 
(Kwak et al., 2018), contrary to 2-Q, which had as many neurospheres as the control 
between the 2 concentrations. Available literature has yet to present the effects of 
dihydropyridines on neurospheres. 
Although most of the drugs tested had neurospheres developing when introduced 
to the cells, a more robust assay could be used to test the effects of the drugs on already 
developed neurospheres (Galli et al., 2004). Some of the targets for neurosphere 
development may be tested in the future, for example, mitochondrial proteins (Jung et al. 

















The synthesis of substituted aromatic and substituted heteroaromatic novel hybrid 
dihydropyridines using the classic Hantzsch reaction was possible with the use of boric 
acid as a catalyst and water/ethanol as a solvent. The substituted styrl group was not 
successfully synthesized as a result of unavailability of cinnamaldehydes commercially 
and the impracticality of the products formed because of the heavy pigmentation and 
stickiness of the products.  
Cheminformatics was used to predict the biological activities of the synthesized 
drugs, which showed all the compounds to be lipophilic, hydrophobic and passable 
according to Lipinski’s rules of oral bioavailability. These predictions also suggested that 
the synthesized dihydropyridines may pass through the blood-brain barrier which would 
be necessary when treating glioblastoma. 
The cell viability assay established the LC50 of the compounds, a pharmacological 
value needed when investigating the toxicity of a drug. This assay also helped establish 
the highest concentration which the cells were growing the same as control, which in this 
case turned out to be 0.00195 mg/ml for all the synthesized and tested (14 compounds) 
dihydropyridine compounds. This concentration was used in invasion, scratch and 
neurosphere assays which investigated the effects of synthesized compounds on cells 




One of the major objectives of this project was to investigate the effects of the 
synthesized dihydropyridines on glioblastoma invasion. The compounds (2-TF, 3-TF, 2-
F, 3-F, and 4-F) were used to test invasion as they had the lowest LC50 concentration.  
This investigation showed 2-TF to have effects on invasion as it had significantly lower 
invasive cell numbers when compared to the control. The rest of the tested compounds 
although they had lower numbers, they did not significantly reduce invasion. These 
results support the scratch assay in which all the drugs seemed to affect cell proliferation 
to the same extent as control. This assay can be improved though to provide quantifiable 
data, which would be useful in performing statistical analysis.  
The 2-TF compound appears to be effective in all the assays, with the lowest LC50 
value showing that it had high cytotoxicity effects, lowered the invasion significantly and 
had lower number of neurospheres developing when treated with 0.00195 mg/ml 
concentration and close to none when treated with LC50. There is a need to further 
investigate the effects of this compound at a molecular level to identify molecular targets. 
 When U-87MG cells were treated with LC50 concentration of 3-Cl and 4-CL 
compounds during neurosphere assay, there was nearly no neurosphere developing. 
These two compounds would be good candidates for further investigations targeting 
proteins involved in neurosphere development. 
Although most of the compounds, did not show effects on reducing invasion, they 
showed cytotoxicity effects through the cell viability test. Further investigation into the 
mode of action of the drugs to establish their molecular targets should be investigated 

















































Berube G. 2016. An overview of molecular hybrids in drug discovery. Expert Opin Drug 
Discov. 11(3):281-305. 
 
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer 
statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 
cancers in 185 countries. CA: a cancer journal for clinicians. 68(6):394-424. 
 
Castro BA, Aghi MK. 2014. Bevacizumab for glioblastoma: Current indications, surgical 
implications, and future directions. Neurosurgical focus. 37(6):E9. 
 
Cattaneo-Pangrazzi RM, Schott H, Wunderli-Allenspach H, Rothen-Rutishauser B, 
Guenthert M, Schwendener RA. 2000. Cell-cycle arrest and p53-independent 
induction of apoptosis in vitro by the new anticancer drugs 5-fdurd-p-fdcydoct 
and dcydpam-p-fdurd in du-145 human prostate cancer cells. J Cancer Res Clin 
Oncol. 126(5):247-256. 
 
Cavalli A, Bolognesi ML. 2009. Neglected tropical diseases: Multi-target-directed 
ligands in the search for novel lead candidates against trypanosoma and 
leishmania. J Med Chem. 52(23):7339-7359. 
 
Chang L, Zhao D, Liu HB, Wang QS, Zhang P, Li CL, Du WZ, Wang HJ, Liu X, Zhang 
ZR. 2015. Activation of sonic hedgehog signaling enhances cell migration and 
invasion by induction of matrix metalloproteinase-2 and-9 via the 
phosphoinositide-3 kinase/akt signaling pathway in glioblastoma corrigendum 
in/mmr/12/5/7815. Molecular medicine reports. 12(5):6702-6710. 
 
Da Fonseca CO, Simao M, Lins IR, Caetano RO, Futuro D, Quirico-Santos T. 2011. 
Efficacy of monoterpene perillyl alcohol upon survival rate of patients with 
recurrent glioblastoma. Journal of cancer research and clinical oncology. 
137(2):287-293. 
 
Demirayak S, Kayagil I, Yurttas L. 2011. Microwave supported synthesis of some novel 
1, 3-diarylpyrazino [1, 2-a] benzimidazole derivatives and investigation of their 
anticancer activities. European journal of medicinal chemistry. 46(1):411-416. 
 
Demuth T, Berens ME. 2004. Molecular mechanisms of glioma cell migration and 
invasion. Journal of neuro-oncology. 70(2):217-228. 
 
Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer 





Firuzi O, Javidnia K, Mansourabadi E, Saso L, Mehdipour AR, Miri R. 2013. Reversal of 
multidrug resistance in cancer cells by novel asymmetrical 1,4-dihydropyridines. 
Archives of pharmacal research. 36(11):1392-1402. 
 
Gallego O. 2015. Nonsurgical treatment of recurrent glioblastoma. Current oncology. 
22(4):e273. 
 
Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, 
Dimeco F, Vescovi A. 2004. Isolation and characterization of tumorigenic, stem-
like neural precursors from human glioblastoma. Cancer research. 64(19):7011-
7021. 
 
Gandalovičová A, Rosel D, Fernandes M, Veselý P, Heneberg P, Čermák V, Petruželka 
L, Kumar S, Sanz-Moreno V, Brábek J. 2017. Migrastatics—anti-metastatic and 
anti-invasion drugs: Promises and challenges. Trends in cancer. 3(6):391-406. 
 
Gediya LK, Njar VC. 2009. Promise and challenges in drug discovery and development 
of hybrid anticancer drugs. Expert opinion on drug discovery. 4(11):1099-1111. 
 
Giese A, Bjerkvig R, Berens M, Westphal M. 2003. Cost of migration: Invasion of 
malignant gliomas and implications for treatment. Journal of clinical oncology. 
21(8):1624-1636. 
 
Gilbert CA, Ross AH. 2009. Cancer stem cells: Cell culture, markers and targets for new 
therapies. Journal of cellular biochemistry. 108(5):1031-1038. 
 
Holbeck SL, Collins JM, Doroshow JH. 2010. Analysis of food and drug administration-
approved anticancer agents in the nci60 panel of human tumor cell lines. 
Molecular cancer therapeutics. 9(5):1451-1460. 
 
Huang H, Hara A, Homma T, Yonekawa Y, Ohgaki H. 2005. Altered expression of 
immune defense genes in pilocytic astrocytomas. Journal of Neuropathology & 
Experimental Neurology. 64(10):891-901. 
 
Issa F, Kassiou M, Rendina LM. 2011. Boron in drug discovery: Carboranes as unique 
pharmacophores in biologically active compounds. Chemical reviews. 
111(9):5701-5722. 
 
Jung N, Kwon HJ, Jung HJ. 2018. Downregulation of mitochondrial uqcrb inhibits cancer 
stem cell-like properties in glioblastoma. International journal of oncology. 
52(1):241-251. 
 
Kaplan MS, Hinds JW. 1977. Neurogenesis in the adult rat: Electron microscopic 





Kim S-S, Pirollo KF, Chang EH. 2015. Isolation and culturing of glioma cancer stem 
cells. Current protocols in cell biology / editorial board, Juan S Bonifacino  [et al]. 
67:23.10.21-23.10.10. 
 
Kleihues P, Ohgaki H. 1999. Primary and secondary glioblastomas: From concept to 
clinical diagnosis. Neuro-oncology. 1(1):44-51. 
 
Kodama T, Ikeda E, Okada A, Ohtsuka T, Shimoda M, Shiomi T, Yoshida K, Nakada M, 
Ohuchi E, Okada Y. 2004. Adam12 is selectively overexpressed in human 
glioblastomas and is associated with glioblastoma cell proliferation and shedding 
of heparin-binding epidermal growth factor. The American journal of pathology. 
165(5):1743-1753. 
 
Kong D-X, Li X-J, Zhang H-Y. 2009. Where is the hope for drug discovery? Let history 
tell the future. Drug discovery today. 14(3-4):115-119. 
 
Kwak SH, Shin S, Lee JH, Shim JK, Kim M, Lee SD, Lee A, Bae J, Park JH, 
Abdelrahman A et al. 2018. Synthesis and structure-activity relationships of 
quinolinone and quinoline-based p2x7 receptor antagonists and their anti-sphere 
formation activities in glioblastoma cells. European journal of medicinal 
chemistry. 151:462-481. 
 
Lara-Velazquez M, Al-Kharboosh R, Jeanneret S, Vazquez-Ramos C, Mahato D, 
Tavanaiepour D, Rahmathulla G, Quinones-Hinojosa A. 2017. Advances in brain 
tumor surgery for glioblastoma in adults. Brain sciences. 7(12):166. 
 
Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ. 2005. 
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand 
resistance via a p21-dependent mechanism in human bladder and prostate cancer 
cells. Cancer research. 65(11):4902-4908. 
 
Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS. 2004. Upregulation of 
tissue inhibitor of metalloproteinases (timp)-2 promotes matrix metalloproteinase 
(mmp)-2 activation and cell invasion in a human glioblastoma cell line. 
Laboratory investigation. 84(1):8. 
 
Martinez ML, Rizzi E, Castro MM, Fernandes K, Bendhack LM, Gerlach RF, Tanus-
Santos JE. 2008. Lercanidipine decreases vascular matrix metalloproteinase-2 
activity and protects against vascular dysfunction in diabetic rats. European 
journal of pharmacology. 599(1-3):110-116. 
 
Meunier B. 2008. Hybrid molecules with a dual mode of action: Dream or reality? 
Accounts of chemical research. 41(1):69-77. 
 





Mihaliak, A. M., Gilbert, C. A., Li, L., Daou, M. C., Moser, R. P., Reeves, A.,Ross, A. H. 
(2010). Clinically relevant doses of chemotherapy agents reversibly block 
formation of glioblastoma neurospheres. Cancer letters, 296(2), 168–177. 
doi:10.1016/j.canlet.2010.04.005 
 
Morgan E, Norman A, Laing K, Seal M. 2017. Treatment and outcomes for glioblastoma 
in elderly compared with non-elderly patients: A population-based study. Current 
Oncology. 24(2):e92. 
 
Muregi FW, Ishih A. 2010. Next-generation antimalarial drugs: Hybrid molecules as a 
new strategy in drug design. Drug Development Research. 71(1):20-32. 
 
Nakamura H, Suenaga N, Taniwaki K, Matsuki H, Yonezawa K, Fujii M, Okada Y, Seiki 
M. 2004. Constitutive and induced cd44 shedding by adam-like proteases and 
membrane-type 1 matrix metalloproteinase. Cancer research. 64(3):876-882. 
 
Naziroglu M, Cig B, Blum W, Vizler C, Buhala A, Marton A, Katona R, Josvay K, 
Schwaller B, Olah Z et al. 2017. Targeting breast cancer cells by mrs1477, a 
positive allosteric modulator of trpv1 channels. PLoS One. 12(6):e0179950. 
 
Niklasson M, Maddalo G, Sramkova Z, Mutlu E, Wee S, Sekyrova P, Schmidt L, Fritz N, 
Dehnisch I, Kyriatzis G et al. 2017. Membrane-depolarizing channel blockers 
induce selective glioma cell death by impairing nutrient transport and unfolded 
protein/amino acid responses. Cancer research. 77(7):1741-1752. 
 
Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre P-L, Burkhard C, 
Schüler D, Probst-Hensch NM, Maiorka PC. 2004. Genetic pathways to 
glioblastoma: A population-based study. Cancer research. 64(19):6892-6899. 
 
Paris D, Bachmeier C, Patel N, Quadros A, Volmar C-H, Laporte V, Ganey J, Beaulieu-
Abdelahad D, Ait-Ghezala G, Crawford F et al. 2011. Selective antihypertensive 
dihydropyridines lower aβ accumulation by targeting both the production and the 
clearance of aβ across the blood-brain barrier. Molecular Medicine. 17(3-4):149-
162. 
 
Pastrana E, Silva-Vargas V, Doetsch F. 2011. Eyes wide open: A critical review of 
sphere-formation as an assay for stem cells. Cell stem cell. 8(5):486-498. 
 
Ramachandran RK, Sørensen MD, Aaberg-Jessen C, Hermansen SK, Kristensen BW. 
2017. Expression and prognostic impact of matrix metalloproteinase-2 (mmp-2) 
in astrocytomas. PLoS One. 12(2):e0172234. 
 
Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML. 2018. A 
perspective on multi-target drug discovery and design for complex diseases. 





Ren Q, Kao V, Grem JL. 1998. Cytotoxicity and DNA fragmentation associated with 
sequential gemcitabine and 5-fluoro-2'-deoxyuridine in ht-29 colon cancer cells. 
Clinical cancer research : an official journal of the American Association for 
Cancer Research. 4(11):2811-2818. 
 
Reynolds BA, Tetzlaff W, Weiss S. 1992. A multipotent egf-responsive striatal 
embryonic progenitor cell produces neurons and astrocytes. Journal of 
Neuroscience. 12(11):4565-4574. 
 
Reynolds BA, Weiss S. 1992. Generation of neurons and astrocytes from isolated cells of 
the adult mammalian central nervous system. science. 255(5052):1707-1710. 
 
Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. 2010. L‐type calcium 
channel blockers and parkinson disease in denmark. Annals of neurology. 
67(5):600-606. 
 
Sarkar S, Nuttall RK, Liu S, Edwards DR, Yong VW. 2006. Tenascin-c stimulates 
glioma cell invasion through matrix metalloproteinase-12. Cancer research. 
66(24):11771-11780. 
 
Scarano W, Duong HT, Lu H, De Souza PL, Stenzel MH. 2013. Folate conjugation to 
polymeric micelles via boronic acid ester to deliver platinum drugs to ovarian 
cancer cell lines. Biomacromolecules. 14(4):962-975. 
 
Scotti L, Mendonca Junior FJ, Ishiki HM, Ribeiro FF, Singla RK, Barbosa Filho JM, Da 
Silva MS, Scotti MT. 2017. Docking studies for multi-target drugs. Current drug 
targets. 18(5):592-604. 
 
Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, 
Brandes AA, Marosi C, Bogdahn U. 2005. Radiotherapy plus concomitant and 
adjuvant temozolomide for glioblastoma. New England Journal of Medicine. 
352(10):987-996. 
 
Takamune Y, Ikebe T, Nagano O, Shinohara M. 2008. Involvement of nf-κb-mediated 
maturation of adam-17 in the invasion of oral squamous cell carcinoma. 
Biochemical and biophysical research communications. 365(2):393-398. 
 
Velena A, Zarkovic N, Gall Troselj K, Bisenieks E, Krauze A, Poikans J, Duburs G. 
2016. 1,4-dihydropyridine derivatives: Dihydronicotinamide analogues-model 
compounds targeting oxidative stress. Oxid Med Cell Longev. 2016:1892412-
1892412. 
 
Verkhratsky A, Butt A. 2013. Glial physiology and pathophysiology. John Wiley & Sons. 
 
Wilson TJ, Zamler DB, Doherty R, Castro MG, Lowenstein PR. 2016. Reversibility of 




behavior: Discovery of a novel neurosphere-specific enzyme, cgmp-dependent 
protein kinase 1, using the genomic landscape of human glioma stem cells as a 
discovery tool. Oncotarget. 7(39):63020. 
 
Woods N, Trevino J, Coppola D, Chellappan S, Yang S, Padmanabhan J. 2015. Fendiline 
inhibits proliferation and invasion of pancreatic cancer cells by interfering with 
adam10 activation and β-catenin signaling. Oncotarget. 6(34):35931-35948. 
 
Zarrin A, Mehdipour AR, Miri R. 2010. Dihydropyridines and multidrug resistance: 
Previous attempts, present state, and future trends. Chemical biology & drug 
design. 76(5):369-381. 
 
Zhang X, Alves DS, Lou J, Hill SD, Barrera FN, Best MD. 2018. Boronic acid liposomes 
for cellular delivery and content release driven by carbohydrate binding. 
Chemical communications (Cambridge, England). 54(48):6169-6172. 
 
Zhang X, Li W, Wang C, Leng X, Lian S, Feng J, Li J, Wang H. 2014. Inhibition of 
autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in 
human glioblastoma u87 and u251 cells. Molecular and cellular biochemistry. 
385(1-2):265-275. 
 
Zhou XF, Yang X, Wang Q, Coburn RA, Morris ME. 2005. Effects of dihydropyridines 
and pyridines on multidrug resistance mediated by breast cancer resistance 
protein: In vitro and in vivo studies. Drug metabolism and disposition: the 
biological fate of chemicals. 33(8):1220-1228. 
 
Zong H, Verhaak RG, Canoll P. 2012. The cellular origin for malignant glioma and 





















Multiple Comparisons 3-PFB 
Dependent Variable:   average cells 















2 control -138.33333* 21.3398
1 
.000 -201.6636 -75.0030 
1 control -138.33333* 21.3398
1 
.000 -201.6636 -75.0030 
0.5 control -138.33333* 21.3398
1 
.000 -201.6636 -75.0030 
0.25 control -138.33333* 21.3398
1 
.000 -201.6636 -75.0030 
0.125 control -101.34333* 21.3398
1 
.001 -164.6736 -38.0130 
0.0625 control -49.00000 21.3398
1 
.192 -112.3303 14.3303 
0.03125 control -4.33333 21.3398
1 
1.000 -67.6636 58.9970 
0.01562 control -13.66667 21.3398
1 
.997 -76.9970 49.6636 
0.00781 control -40.22667 21.3398
1 
.381 -103.5570 23.1036 
0.003906 control -34.00000 21.3398
1 
.568 -97.3303 29.3303 
0.00195 control -2.00000 21.3398
1 
1.000 -65.3303 61.3303 
*. The mean difference is significant at the 0.05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
 
 





Multiple Comparisons 4-FPB 















2 control -148.33333* 15.5790
2 
.000 -194.5673 -102.0994 
1 control -148.33333* 15.5790
2 
.000 -194.5673 -102.0994 
0.5 control -148.33333* 15.5790
2 
.000 -194.5673 -102.0994 
0.25 control -148.33333* 15.5790
2 
.000 -194.5673 -102.0994 
0.125 control -130.77778* 15.5790
2 
.000 -177.0117 -84.5438 
0.0625 control -64.66667* 15.5790
2 
.003 -110.9006 -18.4327 
0.03125 control -17.11111 15.5790
2 
.889 -63.3451 29.1228 
0.01562 control -28.22222 15.5790
2 
.424 -74.4562 18.0117 
0.00781 control -4.66667 15.5790
2 
1.000 -50.9006 41.5673 
0.003906 control -7.66667 15.5790
2 
1.000 -53.9006 38.5673 
0.00195 control -.77778 15.5790
2 
1.000 -47.0117 45.4562 
*. The mean difference is significant at the 0.05 level. 














Multiple Comparisons- 2Q 
Dependent Variable:   averagecells   















2 control -153.55556* 32.5759
6 
.001 -250.2314 -56.8797 
1 control -153.55556* 32.5759
6 
.001 -250.2314 -56.8797 
0.5 control -117.33333* 32.5759
6 
.012 -214.0092 -20.6575 
0.25 control -107.00000* 32.5759
6 
.025 -203.6759 -10.3241 
0.125 control -67.22222 32.5759
6 
.287 -163.8981 29.4537 
0.0625 control -59.77778 32.5759
6 
.410 -156.4537 36.8981 
0.03125 control -34.88889 32.5759
6 
.901 -131.5648 61.7870 
0.01562 control -16.66667 32.5759
6 
.999 -113.3425 80.0092 
0.00781 control -16.11111 32.5759
6 
1.000 -112.7870 80.5648 
0.003906 control -12.11111 32.5759
6 
1.000 -108.7870 84.5648 
0.00195 control -36.89361 32.5759
6 
.871 -133.5695 59.7823 
*. The mean difference is significant at the 0.05 level. 









Multiple Comparisons 5-P 
Dependent Variable:   averagecells   















2 control -132.88889* 26.8519
0 
.000 -212.5775 -53.2003 
1 control -132.88889* 26.8519
0 
.000 -212.5775 -53.2003 
0.5 control -119.77778* 26.8519
0 
.001 -199.4663 -40.0892 
0.25 control -87.55556* 26.8519
0 
.026 -167.2441 -7.8670 
0.125 control -68.44444 26.8519
0 
.119 -148.1330 11.2441 
0.0625 control -58.77778 26.8519
0 
.232 -138.4663 20.9108 
0.03125 control -49.44444 26.8519
0 
.406 -129.1330 30.2441 
0.01562 control -36.77778 26.8519
0 
.725 -116.4663 42.9108 
0.00781 control -41.77778 26.8519
0 
.594 -121.4663 37.9108 
0.003906 control -19.11111 26.8519
0 
.992 -98.7997 60.5775 
0.00195 control -4.00000 26.8519
0 
1.000 -83.6886 75.6886 
*. The mean difference is significant at the 0.05 level. 








Multiple Comparisons 2-F 
Dependent Variable:   averagecells   















2 control -70.11111* 14.8231
0 
.001 -114.1017 -26.1205 
1 control -70.11111* 14.8231
0 
.001 -114.1017 -26.1205 
0.5 control -70.11111* 14.8231
0 
.001 -114.1017 -26.1205 
0.25 control -70.11111* 14.8231
0 
.001 -114.1017 -26.1205 
0.125 control -70.11111* 14.8231
0 
.001 -114.1017 -26.1205 
0.0625 control -69.88889* 14.8231
0 
.001 -113.8795 -25.8983 
0.03125 control -51.22222* 14.8231
0 
.017 -95.2128 -7.2316 
0.01562 control -33.11111 14.8231
0 
.214 -77.1017 10.8795 
0.00781 control -20.22222 14.8231
0 
.729 -64.2128 23.7684 
0.003906 control -16.11111 14.8231
0 
.894 -60.1017 27.8795 
0.00195 control -17.44444 14.8231
0 
.847 -61.4351 26.5462 
*. The mean difference is significant at the 0.05 level. 










Multiple Comparisons 3-F 
Dependent Variable:   averagecells   















2 control -55.44444* 10.5323
5 
.000 -86.7014 -24.1875 
1 control -55.44444* 10.5323
5 
.000 -86.7014 -24.1875 
0.5 control -55.44444* 10.5323
5 
.000 -86.7014 -24.1875 
0.25 control -55.44444* 10.5323
5 
.000 -86.7014 -24.1875 
0.125 control -55.44444* 10.5323
5 
.000 -86.7014 -24.1875 
0.0625 control -55.44444* 10.5323
5 
.000 -86.7014 -24.1875 
0.03125 control -32.77778* 10.5323
5 
.036 -64.0347 -1.5209 
0.01562 control -22.77778 10.5323
5 
.243 -54.0347 8.4791 
0.00781 control -8.55556 10.5323
5 
.980 -39.8125 22.7014 
0.003906 control -4.77778 10.5323
5 
1.000 -36.0347 26.4791 
0.00195 control -18.54578 10.5323
5 
.456 -49.8027 12.7111 
*. The mean difference is significant at the 0.05 level. 











Multiple Comparisons 4-F 
Dependent Variable:   averagecells   















2 control -50.44444* 12.7573
1 
.005 -88.3044 -12.5845 
1 control -50.44444* 12.7573
1 
.005 -88.3044 -12.5845 
0.5 control -50.44444* 12.7573
1 
.005 -88.3044 -12.5845 
0.25 control -50.44444* 12.7573
1 
.005 -88.3044 -12.5845 
0.125 control -50.44444* 12.7573
1 
.005 -88.3044 -12.5845 
0.0625 control -44.44444* 12.7573
1 
.016 -82.3044 -6.5845 
0.03125 control -15.11111 12.7573
1 
.843 -52.9711 22.7488 
0.01562 control -6.88889 12.7573
1 
.999 -44.7488 30.9711 
0.00781 control .11111 12.7573
1 
1.000 -37.7488 37.9711 
0.003906 control -13.11111 12.7573
1 
.920 -50.9711 24.7488 
0.00195 control -1.88889 12.7573
1 
1.000 -39.7488 35.9711 
*. The mean difference is significant at the 0.05 level. 











Multiple Comparisons 2,3-DF 
Dependent Variable:   averagecells   















2 control -72.00000* 11.7605
6 
.000 -106.9019 -37.0981 
1 control -72.00000* 11.7605
6 
.000 -106.9019 -37.0981 
0.5 control -72.00000* 11.7605
6 
.000 -106.9019 -37.0981 
0.25 control -72.00000* 11.7605
6 
.000 -106.9019 -37.0981 
0.125 control -72.00000* 11.7605
6 
.000 -106.9019 -37.0981 
0.0625 control -72.00000* 11.7605
6 
.000 -106.9019 -37.0981 
0.03125 control -70.77778* 11.7605
6 
.000 -105.6797 -35.8759 
0.01562 control -31.77778 11.7605
6 
.087 -66.6797 3.1241 
0.00781 control -20.00000 11.7605
6 
.495 -54.9019 14.9019 
0.003906 control -8.55556 11.7605
6 
.991 -43.4574 26.3463 
0.00195 control -9.44444 11.7605
6 
.982 -44.3463 25.4574 
*. The mean difference is significant at the 0.05 level. 












Multiple Comparisons 2,4-DF 
Dependent Variable:   averagecells   















2 control -90.88889* 13.2361
9 
.000 -130.1700 -51.6078 
1 control -90.88889* 13.2361
9 
.000 -130.1700 -51.6078 
0.5 control -90.88889* 13.2361
9 
.000 -130.1700 -51.6078 
0.25 control -90.88889* 13.2361
9 
.000 -130.1700 -51.6078 
0.125 control -90.88889* 13.2361
9 
.000 -130.1700 -51.6078 
0.0625 control -90.88889* 13.2361
9 
.000 -130.1700 -51.6078 
0.03125 control -51.88889* 13.2361
9 
.006 -91.1700 -12.6078 
0.01562 control -4.00000 13.2361
9 
1.000 -43.2811 35.2811 
0.00781 control -23.77778 13.2361
9 
.434 -63.0589 15.5033 
0.003906 control -1.77778 13.2361
9 
1.000 -41.0589 37.5033 
0.00195 control -28.33351 13.2361
9 
.252 -67.6146 10.9476 
*. The mean difference is significant at the 0.05 level. 









Multiple Comparisons 2,5-DF 
Dependent Variable:   averagecells   















2 control -112.77778* 12.8084
2 
.000 -150.7894 -74.7662 
1 control -112.77778* 12.8084
2 
.000 -150.7894 -74.7662 
0.5 control -112.77778* 12.8084
2 
.000 -150.7894 -74.7662 
0.25 control -112.77778* 12.8084
2 
.000 -150.7894 -74.7662 
0.125 control -112.77778* 12.8084
2 
.000 -150.7894 -74.7662 
0.0625 control -112.77778* 12.8084
2 
.000 -150.7894 -74.7662 
0.03125 control -61.22222* 12.8084
2 
.001 -99.2338 -23.2106 
0.01562 control -32.11111 12.8084
2 
.129 -70.1227 5.9005 
0.00781 control -32.77778 12.8084
2 
.116 -70.7894 5.2338 
0.003906 control -6.44444 12.8084
2 
1.000 -44.4561 31.5672 
0.00195 control -20.22222 12.8084
2 
.578 -58.2338 17.7894 
*. The mean difference is significant at the 0.05 level. 












Multiple Comparisons- 2-TF 
Dependent Variable:   averagecells   

















2 control -239.22222* 30.2928
8 
.000 -329.1226 -149.3219 
1 control -239.22222* 30.2928
8 
.000 -329.1226 -149.3219 
0.5 control -239.22222* 30.2928
8 
.000 -329.1226 -149.3219 
0.25 control -239.22222* 30.2928
8 
.000 -329.1226 -149.3219 
0.125 control -239.22222* 30.2928
8 
.000 -329.1226 -149.3219 
0.0625 control -239.22222* 30.2928
8 
.000 -329.1226 -149.3219 
0.03125 control -227.88889* 30.2928
8 
.000 -317.7893 -137.9885 
0.01562 control -158.77778* 30.2928
8 
.000 -248.6781 -68.8774 
0.00781 control -105.77778* 30.2928
8 
.015 -195.6781 -15.8774 
0.003906 control -80.44444 30.2928
8 
.096 -170.3448 9.4559 
0.00195 control -61.33333 30.2928
8 
.306 -151.2337 28.5670 
*. The mean difference is significant at the 0.05 level. 











Multiple Comparisons 2-TF 
Dependent Variable:   averagecells   















2 control -208.00000* 31.9869
8 
.000 -302.9280 -113.0720 
1 control -208.00000* 31.9869
8 
.000 -302.9280 -113.0720 
0.5 control -208.00000* 31.9869
8 
.000 -302.9280 -113.0720 
0.25 control -208.00000* 31.9869
8 
.000 -302.9280 -113.0720 
0.125 control -208.00000* 31.9869
8 
.000 -302.9280 -113.0720 
0.0625 control -208.00000* 31.9869
8 
.000 -302.9280 -113.0720 
0.03125 control -206.55556* 31.9869
8 
.000 -301.4835 -111.6276 
0.01562 control -99.44444* 31.9869
8 
.037 -194.3724 -4.5165 
0.00781 control -75.11111 31.9869
8 
.174 -170.0391 19.8168 
0.003906 control -48.77778 31.9869
8 
.616 -143.7057 46.1502 
0.00195 control -66.98245 31.9869
8 
.273 -161.9104 27.9455 
*. The mean difference is significant at the 0.05 level. 












Multiple Comparisons 3-Cl 
Dependent Variable:   averagecells   















2 control -230.44444* 42.8329
9 
.000 -357.5602 -103.3287 
1 control -230.44444* 42.8329
9 
.000 -357.5602 -103.3287 
0.5 control -230.44444* 42.8329
9 
.000 -357.5602 -103.3287 
0.25 control -230.44444* 42.8329
9 
.000 -357.5602 -103.3287 
0.125 control -230.44444* 42.8329
9 
.000 -357.5602 -103.3287 
0.0625 control -230.44444* 42.8329
9 
.000 -357.5602 -103.3287 
0.03125 control -195.11111* 42.8329
9 
.001 -322.2268 -67.9954 
0.01562 control -96.88889 42.8329
9 
.204 -224.0046 30.2268 
0.00781 control -75.88889 42.8329
9 
.449 -203.0046 51.2268 
0.003906 control -28.88889 42.8329
9 
.995 -156.0046 98.2268 
0.00195 control 38.77778 42.8329
9 
.961 -88.3379 165.8935 
*. The mean difference is significant at the 0.05 level. 











Multiple Comparisons 4-Cl 
Dependent Variable:   averagecells   















2 control -227.66667* 33.4481
4 
.000 -326.9309 -128.4024 
1 control -227.66667* 33.4481
4 
.000 -326.9309 -128.4024 
0.5 control -227.66667* 33.4481
4 
.000 -326.9309 -128.4024 
0.25 control -227.66667* 33.4481
4 
.000 -326.9309 -128.4024 
0.125 control -227.66667* 33.4481
4 
.000 -326.9309 -128.4024 
0.0625 control -227.66667* 33.4481
4 
.000 -326.9309 -128.4024 
0.03125 control -223.55556* 33.4481
4 
.000 -322.8198 -124.2913 
0.01562 control -84.22222 33.4481
4 
.126 -183.4865 15.0420 
0.00781 control -38.33333 33.4481
4 
.864 -137.5976 60.9309 
0.003906 control -22.44444 33.4481
4 
.995 -121.7087 76.8198 
0.00195 control .33333 33.4481
4 
1.000 -98.9309 99.5976 
*. The mean difference is significant at the 0.05 level. 










Multiple Comparisons EAA 
Dependent Variable:   averagecells   
















2 control -81.88889* 19.8141
6 
.003 -140.6915 -23.0863 
1 control -69.55556* 19.8141
6 
.015 -128.3582 -10.7530 
0.5 control -40.44444 19.8141
6 
.298 -99.2470 18.3582 
0.25 control -38.66667 19.8141
6 
.344 -97.4693 20.1359 
0.125 control -29.00000 19.8141
6 
.660 -87.8026 29.8026 
0.0625 control -10.44444 19.8141
6 
.999 -69.2470 48.3582 
0.03125 control -24.00000 19.8141
6 
.827 -82.8026 34.8026 
0.01562 control -11.55556 19.8141
6 
.998 -70.3582 47.2470 
0.00781 control -13.88889 19.8141
6 
.993 -72.6915 44.9137 
0.003906 control -1.88889 19.8141
6 
1.000 -60.6915 56.9137 
0.00195 control 2.66667 19.8141
6 
1.000 -56.1359 61.4693 
*. The mean difference is significant at the 0.05 level. 

























2-TF 3-TF -754.19333 684.396
33 





1.000 -3555.2831 1439.2898 
3-F -769.70333 684.396
33 











.016 -5428.8764 -434.3036 
3-TF 2-TF 754.19333 684.396
33 
1.000 -1743.0931 3251.4798 
2-F -303.80333 684.396
33 
1.000 -2801.0898 2193.4831 
3-F -15.51000 684.396
33 
1.000 -2512.7964 2481.7764 
4-F -413.07000 684.396
33 





.118 -4674.6831 319.8898 
2-F 2-TF 1057.99667 684.396
33 
1.000 -1439.2898 3555.2831 
3-TF 303.80333 684.396
33 
1.000 -2193.4831 2801.0898 
3-F 288.29333 684.396
33 
1.000 -2208.9931 2785.5798 
4-F -109.26667 684.396
33 





.270 -4370.8798 623.6931 
3-F 2-TF 769.70333 684.396
33 
1.000 -1727.5831 3266.9898 
3-TF 15.51000 684.396
33 
1.000 -2481.7764 2512.7964 
2-F -288.29333 684.396
33 
1.000 -2785.5798 2208.9931 
4-F -397.56000 684.396
33 





.124 -4659.1731 335.3998 
4-F 2-TF 1167.26333 684.396
33 
1.000 -1330.0231 3664.5498 
3-TF 413.07000 684.396
33 
1.000 -2084.2164 2910.3564 
2-F 109.26667 684.396
33 
1.000 -2388.0198 2606.5531 
3-F 397.56000 684.396
33 
















.118 -319.8898 4674.6831 
2-F 1873.59333 684.396
33 
.270 -623.6931 4370.8798 
3-F 2161.88667 684.396
33 
.124 -335.3998 4659.1731 
4-F 1764.32667 684.396
33 
.363 -732.9598 4261.6131 
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APPENDIX B 
 
3-FPB 
 
 
 
 
 
 
80 
 
 
 
4-FPB 
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2-F 
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2,3-DF 
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2,4-DF 
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2,5-DF 
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2-TF 
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3-TF 
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3-Cl 
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4-Cl 
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4-Q 
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5-M2F 
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5-M2-TF 
 
 
 
 
 
96 
 
 
 
EAA 
 
 
 
 
 
